GB-70985 | October 2025
For UK HCPs only.
Click here for references and abbreviations.
Click here for prescribing information and adverse event reporting information.
Find out more
BTS/NICE/SIGN 2024 guideline
now published and recommending
ICS/Formoterol across the asthma pathway for new patients
aged 12 and over.1
BTS/NICE/SIGN 2024 guideline
now published and recommending
ICS/Formoterol across the asthma pathway for new patients
aged 12 and over.1
Find out more
For UK HCPs only.
Click here for references and abbreviations.
Click here for prescribing information and adverse event reporting information.
Find out more
BTS/NICE/SIGN 2024 guideline
now published and recommending
ICS/Formoterol across the asthma pathway for new patients
aged 12 and over.1
Symbicort® (budesonide/formoterol)
Turbohaler®
Find out more
with you every step of the way
from age 12 and over – as per 2024 BTS/NICE/SIGN guideline 1
Reliever Therapy (200/6 only)3 & MART (100/6 & 200/6 only) 2,3
GB-70985 | October 2025
GB-70985 | October 2025
For UK HCPs only.
Click here for references and abbreviations.
Click here for prescribing information and adverse event reporting information.
Symbicort® (budesonide/formoterol) Turbohaler® 100/6 and 200/6 are indicated for adults and adolescents 12 years and older for regular treatment of asthma where the combined use of inhaled corticosteroids (ICS) and long-acting β2 adrenoceptor agonist (LABA) is appropriate:2,3
- Patients not adequately controlled with ICS and as needed inhaled short-acting β2 adrenoceptor agonists (SABA); or -Patients already adequately controlled on both ICS and LABA.
Symbicort® Turbohaler® 100/6 is indicated for adult, adolescents and children aged 6 years and older. Symbicort® Turbohaler® 200/6 is indicated for adults and adolescents 12 years and older.
Symbicort® Turbohaler® 100/6 is not intended for the initial management of asthma. It is indicated in patients with asthma aged ≥6 years for regular maintenance treatment with a separate rapid-acting bronchodilator as rescue or as a Maintenance and Reliever Therapy (MART). 1
Symbicort® Turbohaler® 200/6 is indicated for patients ≥12 years as reliever therapy for mild asthma and is indicated for maintenance therapy or MART. 2
You are strongly advised to consult the respective SmPCs before prescribing for age related dosing, maximum dosage and method of administration for Symbicort Turbohaler 100/6 and 200/6. 2,3